Jefferies analyst Daniel Rizzo initiates coverage on $AptarGroup (ATR.US)$ with a buy rating, and sets the target price at $215.
According to TipRanks data, the analyst has a success rate of 68.0% and a total average return of 16.5% over the past year.
Furthermore, according to the comprehensive report, the opinions of $AptarGroup (ATR.US)$'s main analysts recently are as follows:
In discussing the packaging and containers industry ahead of quarterly results, it is believed that the third quarter saw a sequential improvement in demand, though expectations are tempered due to consumer and industrial sector caution. The perspective is that the industry's most challenging period has passed, but forecasts remain conservative with the anticipation of volumes remaining steady, rather than a low single-digit increase for the year. A full recovery is projected to extend into the first half of 2025, with a preference for certain companies in the sector as the ones to watch as the quarter's results approach.
AptarGroup's Pharma segment is anticipated to spearhead an 8.5% annual EBITDA growth through 2026, driven by a robust pipeline of new products including delivery systems for GLP-1 drugs, over-the-counter Narcan, and Neffy. This growth is expected to align the stock's valuation more closely with its peers in the healthcare packaging sector.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
富瑞集團分析師Daniel Rizzo首次給予$AptarGroup (ATR.US)$買入評級，目標價215美元。
根據TipRanks數據顯示，該分析師近一年總勝率為68.0%，總平均回報率為16.5%。
此外，綜合報道，$AptarGroup (ATR.US)$近期主要分析師觀點如下：
在季度業績公佈之前討論包裝和容器行業時，人們認爲第三季度的需求連續改善，儘管由於消費者和工業部門的謹慎態度，預期有所減弱。前景是，該行業最具挑戰性的時期已經過去，但預測仍然保守，預計今年的銷量將保持穩定，而不是個位數的低增長。預計全面復甦將持續到2025年上半年，隨着本季度業績的臨近，該行業的某些公司將優先考慮該行業的某些公司。
預計到2026年，AptarGroup的製藥板塊將帶頭實現8.5％的年度息稅折舊攤銷前利潤增長，這得益於包括 GLP-1 藥物輸送系統、非處方Narcan和Neffy在內的強大新產品管線。預計這種增長將使該股的估值與醫療保健包裝領域的同行更加接近。
提示:
TipRanks為獨立第三方，提供金融分析師的分析數據，並計算分析師推薦的平均回報率和勝率。提供的信息並非投資建議，僅供参考。本文不對評級數據和報告的完整性與準確性做出認可、聲明或保證。
TipRanks提供每位分析師的星級，分析師星級代表分析師所有推薦的過往表現，通過分析師的總勝率和平均回報率综合計算得出，星星越多，則該分析師過往表現越優異，最高爲5颗星。
分析師總勝率為近一年分析師的評級成功次數占總評級次數的比率。評级的成功與否，取決於TipRanks的虚擬投資組合是否從該股票中產生正回報。
總平均回報率為基於分析師的初始評級創建虚擬投資組合，並根據評級變化對組合進行調整，在近一年中該投資組合所獲得的回報率。
